Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A transition-state analog inhibitor of purine nucleoside phosphorylase that is being developed to treat chronic lymphocytic leukemia.

Etymologies

Sorry, no etymologies found.

Examples

  • BioCryst is also conducting late-stage trials of a skin cancer treatment called forodesine, and a gout drug candidate designated BCX4208.

  • This decrease was driven by lower development costs associated with the peramivir and forodesine clinical programs following the completion of various clinical studies during 2010, partially offset by higher BCX4208 gout program development costs.

  • BioCryst currently has three novel late-stage compounds: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase PNP inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies.

  • Additionally, forodesine HCl is being studied in a phase II trial with an oral formulation in Chronic Lymphocytic

    THE MEDICAL NEWS

  • The Company's product candidate, forodesine HCl, is a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP).

    THE MEDICAL NEWS

  • BioCryst has progressed two novel compounds that are in late-stage pivotal trials; peramivir, a neuraminidase inhibitor for the treatment of influenza, and forodesine, an orally-available purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).

    Medindia Health News

  • BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available

    BioCryst Pharmaceuticals to Announce Third Quarter 2010 Financial Results on October 28, 2010 - Yahoo! Finance

  • These increases in R&D expenses were partially offset by a decrease of $2.1 million in development costs associated with the forodesine program.

    BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update - Yahoo! Finance

  • In the pivotal Phase 2 study of 200 mg once-daily forodesine in the treatment of CTCL, eleven percent of late-stage patients (Stage IIB to IVA) achieved a partial cutaneous response.

    BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update - Yahoo! Finance

  • An interim analysis of the ongoing exploratory Phase 2 study evaluating 200 mg of forodesine twice-daily in 25 patients with CLL showed that three patients demonstrated a confirmed partial response to forodesine.

    BioCryst Reports Third Quarter 2010 Financial Results and Provides Corporate Update - Yahoo! Finance

Wordnik is becoming a not-for-profit! Read our announcement here.

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.